Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


03.10.2017

2 Ann Oncol
4 BMC Cancer
4 Cancer Res
1 Clin Cancer Res
6 Gynecol Oncol
1 Hum Pathol
3 Oncogene
1 Oncology
3 PLoS One
1 Tumour Biol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    

  2. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. HICKS DA, Galimanis CE, Webb PG, Spillman MA, et al
    Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration.
    BMC Cancer. 2016;16:788.
    PubMed     Text format     Abstract available

  4. DROESER RA, Mechera R, Daster S, Weixler B, et al
    MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
    BMC Cancer. 2016;16:639.
    PubMed     Text format     Abstract available

  5. NOTARO S, Reimer D, Fiegl H, Schmid G, et al
    Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
    BMC Cancer. 2016;16:589.
    PubMed     Text format     Abstract available

  6. SHEN CC, Hu LY, Yang AC, Chiang YY, et al
    Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
    BMC Cancer. 2016;16:839.
    PubMed     Text format     Abstract available


    Cancer Res

  7. FALCETTA F, Bizzaro F, D'Agostini E, Bani MR, et al
    Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer.
    Cancer Res. 2017 Sep 26. pii: canres.1099.2017.
    PubMed     Text format     Abstract available

  8. PIACENTE F, Caffa I, Ravera S, Sociali G, et al
    Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Cancer Res. 2017;77:3857-3869.
    PubMed     Text format     Abstract available

  9. ETEMADMOGHADAM D, Azar WJ, Lei Y, Moujaber T, et al
    EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas.
    Cancer Res. 2017 Jun 23. pii: canres.2224.2016.
    PubMed     Text format     Abstract available

  10. RIVERA B, Di Iorio M, Frankum J, Nadaf J, et al
    Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma.
    Cancer Res. 2017 Jun 23. pii: canres.0190.2017.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  11. HAO D, Li J, Jia S, Meng Y, et al
    Integrated analysis reveals tubal and ovarian originated serous ovarian cancer and predicts differential therapeutic responses.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0638.2017.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  12. MENDERES G, Bonazzoli E, Bellone S, Altwerger G, et al
    Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
    Gynecol Oncol. 2017 Jul 10. pii: S0090-8258(17)31026.
    PubMed     Text format     Abstract available

  13. NASIOUDIS D, Chapman-Davis E, Frey MK, Caputo TA, et al
    Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?
    Gynecol Oncol. 2017 Jul 14. pii: S0090-8258(17)31161.
    PubMed     Text format     Abstract available

  14. HOGEN L, Brar H, Covens A, Bassiouny D, et al
    Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma?
    Gynecol Oncol. 2017 Jul 28. pii: S0090-8258(17)31168.
    PubMed     Text format     Abstract available

  15. FADER AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, et al
    Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Gynecol Oncol. 2017 Jul 30. pii: S0090-8258(17)31167.
    PubMed     Text format     Abstract available

  16. BARBER EL, Rossi EC, Gehrig PA
    Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31340.
    PubMed     Text format     Abstract available

  17. RUSTIN G, Vergote I, Micha JP, Duska LR, et al
    A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31264.
    PubMed     Text format     Abstract available


    Hum Pathol

  18. ROTH LM, Lyu B, Cheng L
    Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms.
    Hum Pathol. 2017 Apr 23. pii: S0046-8177(17)30125.
    PubMed     Text format     Abstract available


    Oncogene

  19. GURLER MAIN H, Xie J, Muralidhar GG, Elfituri O, et al
    Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
    Oncogene. 2016 Dec 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available

  20. SHANG Y, He J, Wang Y, Feng Q, et al
    CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available

  21. NIU N, Mercado-Uribe I, Liu J
    Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncology

  22. MARCHETTI C, Musella A, Romito A, Vertechy L, et al
    Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
    Oncology. 2017 Sep 26. doi: 10.1159/000475668.
    PubMed     Text format     Abstract available


    PLoS One

  23. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    PubMed     Text format     Abstract available

  24. ZHU XM, Sun WF
    Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.
    PLoS One. 2017;12:e0185456.
    PubMed     Text format     Abstract available

  25. TAO X, Chen L, Ge S, Cai L, et al
    Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis.
    PLoS One. 2017;12:e0177426.
    PubMed     Text format     Abstract available


    Tumour Biol

  26. MARQUES DS, Grativol J, Alves da Silva Peres R, da Rocha Matos A, et al
    Osteopontin-c isoform levels are associated with SR and hnRNP differential expression in ovarian cancer cell lines.
    Tumour Biol. 2017;39:1010428317725442.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: